Traws Pharma Advances Antiviral Programs Amid Revenue Growth

Traws Pharma, Inc. ( (TRAW) ) has released its Q2 earnings. Here is a breakdown of the information Traws Pharma, Inc. presented to its investors.

Traws Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing novel antiviral therapies targeting respiratory viral diseases, including COVID-19 and influenza. In its latest earnings report, Traws Pharma highlighted its strategic focus on advancing its antiviral programs, particularly ratutrelvir for COVID-19 and tivoxavir marboxil for influenza. The company reported significant progress in its clinical trials, with a Phase 2 study for ratutrelvir set to begin soon, and ongoing discussions with BARDA for stockpiling tivoxavir marboxil. Financially, Traws Pharma saw a substantial increase in revenue to $2.7 million for the second quarter of 2025, primarily due to deferred revenue recognition, while reducing its net loss significantly compared to the previous year. Looking ahead, Traws Pharma remains committed to advancing its antiviral candidates and exploring partnership opportunities for its legacy oncology programs, aiming to address unmet medical needs in the treatment of viral diseases.